Genmab (GMAB) analyst forecast and price target
Analyst forecast
Consensus of 29 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $42.00 from $40.00 | Aug 7, 2026 |
| TD Cowen | Upgraded | Hold → Buy | $43.00 from $32.00 | Jul 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 from $38.00 | Jul 2, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $38.00 | Jun 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $38.00 from $40.00 | Apr 30, 2026 |
| Wolfe Research | Initiated Coverage | Outperform | $32.00 | Mar 27, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $40.00 | Mar 2, 2026 |
| Guggenheim | Maintained | Buy | $40.00 from $45.00 | Feb 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 from $39.00 | Feb 18, 2026 |
| Jefferies | Maintained | Buy | $41.50 | Feb 17, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $34.00 | Feb 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $39.00 | Jan 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $39.00 from $41.00 | Jan 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $41.00 from $40.00 | Nov 10, 2025 |
| Truist Securities | Maintained | Buy | $48.00 from $49.00 | Nov 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | Oct 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 from $36.00 | Oct 2, 2025 |
| Guggenheim | Upgraded | Neutral → Buy | $43.00 | Sep 24, 2025 |
| Guggenheim | Upgraded | Neutral → Buy | $43.00 | Sep 23, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $36.00 from $35.00 | Aug 15, 2025 |
Frequently asked questions
What is the price target for GMAB stock?
The average 12-month analyst price target for Genmab (GMAB) is $41.67, with a high estimate of $43.00 and a low of $40.00, across 3 analysts.
Is GMAB a buy, sell, or hold?
Analysts covering Genmab currently average a Buy rating: 26 buy, 3 hold and 0 sell, from 29 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for GMAB?
The average price target of $41.67 implies 25.82% upside from the last price of $33.12.
What is the latest analyst rating on GMAB?
On Aug 7, 2026, Guggenheim maintained Genmab at Buy with a price target of $42.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.